What is Leerink Partnrs’ Estimate for MLTX FY2029 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of $8.17 per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

A number of other research firms have also commented on MLTX. Wedbush reaffirmed an “outperform” rating and issued a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th. Finally, The Goldman Sachs Group raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $62.00 to $82.00 in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Buy” and an average price target of $84.29.

MoonLake Immunotherapeutics Trading Up 1.0 %

MoonLake Immunotherapeutics stock opened at $47.11 on Friday. The firm has a 50 day simple moving average of $50.02 and a 200 day simple moving average of $49.04. MoonLake Immunotherapeutics has a 1-year low of $37.55 and a 1-year high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the prior year, the firm earned ($0.18) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE bought a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $44,000. Barclays PLC raised its position in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after buying an additional 5,229 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of MoonLake Immunotherapeutics by 26.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock worth $655,000 after acquiring an additional 2,700 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in MoonLake Immunotherapeutics in the third quarter worth $706,000. Finally, Erste Asset Management GmbH purchased a new position in MoonLake Immunotherapeutics in the third quarter worth $741,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.